For UK clinicians the comparison starts with an availability fact: OpenEvidence withdrew from the UK and EU in April 2026 citing regulatory uncertainty, and it remains unavailable here as of July 2026. GPnotebook AI Answers, by contrast, launched into the UK market it was built for. The architectural comparison is still worth making, because it clarifies what each kind of tool is for, and because many UK doctors used OpenEvidence before the withdrawal and want to know what maps onto what.
Source breadth: archive versus literature
GPnotebook AI Answers primarily synthesises GPnotebook's own GP-authored clinical library of more than 35,000 articles, supplementing where needed with authoritative sources such as NICE. OpenEvidence is principally a broad clinical evidence and literature-answer engine, grounded in peer-reviewed research with major publisher partnerships. One draws on a bounded, curated, primary-care-shaped corpus; the other on a vast research literature. Neither breadth nor curation is automatically more accurate; they fail in different ways. A curated archive can lag or compress; a literature engine can surface evidence that is real but wrong for your jurisdiction or your patient.
Intended setting
GPnotebook is UK primary care to its core: the articles are written for GP questions, in GP language, at GP consultation tempo. OpenEvidence grew up in US practice, where it achieved remarkable penetration among physicians, and its centre of gravity is international literature synthesis rather than UK pathway navigation. The distinction matters most exactly where UK GPs need answers most: referral thresholds, prescribing norms and pathway wording that are jurisdiction-specific.
Answer styles
The products read differently. GPnotebook returns a concise primary-care summary with links to its own supporting pages. OpenEvidence returns a broader evidence synthesis with research citations, closer to a rapid literature review than a pathway answer. If your question is what do I do next in a UK surgery, the first style fits. If your question is what does the evidence say about this treatment effect, the second does.
Trust models
GPnotebook's trust rests on an internally curated, clinician-authored archive with decades of editorial history: you trust the answer because you trust the library. OpenEvidence's trust rests on direct retrieval across a large evidence corpus with citations to the research itself: you trust the answer because you can inspect the evidence. Both are legitimate, and both still require the clinician to check jurisdiction, currency and applicability.
The scale of what withdrew
It is worth being clear about what UK clinicians lost, because it explains the volume of searches this comparison still attracts. Before the withdrawal, OpenEvidence had become the fastest-growing clinical information tool in US medicine, reportedly used daily by a large share of American physicians across thousands of hospitals, handling clinical query volumes in the millions per month, and capitalised in early 2026 at one of the highest valuations in health AI. Its publisher partnerships gave its literature synthesis unusual credibility. None of that transferred to the UK: the company judged the regulatory environment too uncertain and switched access off rather than adapting to it. Whether it returns will depend on how the UK's evolving medical-device and AI frameworks settle, and any return would still leave the jurisdiction problem: a literature engine tuned to US practice does not become a UK pathway tool by re-enabling logins.
When each would be the better choice
GPnotebook AI Answers is preferable for common primary-care management, quick referral or drug-switch questions, and clinicians who want familiar GPnotebook wording with a curated pedigree. OpenEvidence, where available, suits new research questions, specialist uncertainty, and topics that concise primary-care summaries do not cover. For UK clinicians today the second column is largely theoretical, and literature-style alternatives that remain accessible are covered in our post-withdrawal analysis.
Mapping former OpenEvidence habits onto available tools
For UK doctors who used OpenEvidence before April 2026, the practical replacement is a mapping exercise rather than a single substitute. The literature-synthesis habit, what does the recent evidence say, maps to a currently accessible literature engine such as Vera Health or to institutional evidence summaries. The pathway habit, what do I do next for this patient in a UK setting, was never OpenEvidence's strength and maps to the UK-grounded layer: GPnotebook AI Answers for curated primary-care explanation, iatroX for answers cited to national guidance directly. The drug-detail habit maps to the SmPC/eMC entry, which no synthesis layer should replace for dosing decisions. Splitting the use cases this way usually leaves clinicians better served than the single-tool habit did, because each question now goes to the layer built for it.
The UK middle ground
There is a third position between an internal encyclopaedia and a global literature engine: conversational synthesis grounded directly in the UK guidance layer. Ask iatroX retrieves from NICE, CKS, SmPC/eMC, MHRA, SIGN and NHS content and cites those sources under each answer, giving UK clinicians literature-engine convenience with jurisdiction built in rather than bolted on. For the daily questions of UK practice, that middle ground is usually where the answer actually lives.